The Pipeline

Home>News>The Pipeline

Global IP takes centre stage at the 21st Advanced Summit on Life Sciences Patents

Cartherics’ Director of IP & Licensing, Telma Mantas recently attended the ACI’s 21st Advanced Summit on Life Sciences Patents in New York City. The summit provided the opportunity to engage in face-to-face discussions with leading stakeholders on the best practices to enhance global protections for patent portfolios. Now more than ever in these increasingly […]

2023-05-30T15:08:10+10:00May 30th, 2023|

Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China

Melbourne, Australia, 28 April 2023 –  Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd (“Shunxi”) a licence to develop, manufacture and commercialise Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including […]

2023-04-28T13:00:59+10:00April 28th, 2023|

Cartherics proudly supports the White Shirt Campaign

Cartherics is hosting a White Shirt Day lunch on 8th May to help raise funds and awareness for ovarian cancer. The White Shirt Campaign officially launches on April 11th and culminates on White Shirt Day (8 May) – World Ovarian Cancer Day.

The campaign is a 15-year partnership between the Ovarian Cancer Research Foundation (OCRF) […]

2023-05-24T13:40:22+10:00April 11th, 2023|

Cartherics to present at ThymOz 2023

Cartherics will be presenting at the ThymOZ 2023 International Conference on T Cells to be held from 22 -26 March at Heron Island in Queensland, Australia. The conference covers a broad range of topics including T cell differentiation and function, stromal cell biology, immunotherapy and tissue regeneration.

Rachelle Duffin, PhD Candidate at Cartherics will be presenting […]

2023-03-22T09:32:06+11:00March 22nd, 2023|

Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Ovarian Cancer

Melbourne, Victoria, Australia 27 February 2023

Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer.

The clinical trial to be conducted by Peter Mac will be the first […]

2023-02-27T14:37:49+11:00February 27th, 2023|

Cartherics is ‘Turning Teal’ this February in support of ovarian cancer

Cartherics is delighted to be hosting a Teal Tea this February to raise awareness and funds for people affected by ovarian cancer.

Ovarian Cancer Australia’s Teal Ribbon Day is an initiative that aims to start conversations that change lives. It will increase awareness of the disease and help raise funds to support people affected by […]

2023-05-24T13:40:58+10:00February 22nd, 2023|

Cartherics celebrates PhD student’s success

Cartherics is delighted to announce that Saleh Almasabi has successfully completed his PhD Candidature.

Saleh’s research thesis, The role of integrin linked kinase in senescence and immunosuppressive tumor microenvironment in colon cancer’, identified that integrin-linked kinase (ILK) is associated with cancer prognosis and characterises the immunosuppressive tumor microenvironment. These findings suggest possible clinical avenues of targeting […]

2023-02-06T13:37:22+11:00February 6th, 2023|

Cartherics granted first patent in China for multiple development candidates

Melbourne, Australia, 09 January 2023Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent filing WO2017088012.

The […]

2023-01-09T14:10:25+11:00January 9th, 2023|

Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma

Melbourne, Victoria, Australia – 08 November 2022

The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).

“Patients with advanced stages of cutaneous T-cell lymphomas often […]

2022-11-09T10:04:56+11:00November 8th, 2022|

Cartherics is ‘Frocking Up’ this month in support of ovarian cancer research

Cartherics is delighted to be participating in Frocktober – Australia’s most fashionable month-long fundraiser to raise awareness and funds for vital ovarian cancer research through the Ovarian Cancer Research Foundation (OCRF).

Ovarian cancer is Australia’s most lethal gynaecological cancer, taking more than 1,000 lives each year. With a five-year survival rate of only 48%, there […]

2022-10-17T11:29:29+11:00October 17th, 2022|
Go to Top